Læknablaðið - 15.01.2012, Blaðsíða 37

Y F I R L I T
Heimildir
1. Willis T. De anima brutorum. Davis, London 1672.
2. Oppenheim H. Lehrbuch der Nervenkrankheiten. Karger,
Berlin 1774.
3. Beard GM. Neurasthenia, or nervous exhaustion. Boston
Med Surg J 1869; 80: 217-21.
4. Ekbom KA. Asthenia crurum paraesthetica (Irritable legs).
Acta Mcd Scand 1944; 118:197-209.
5. Ekbom KA. Restless legs. Acta Med Scand 1945; Suppl.158:
1-123.
6. Ekbom KA. Restless legs syndrome. Neurology 1960; 10:
868-73.
7. Lavigne GJ, Montplaisir JY. Restless legs syndrome
and sleep bruxism: prevalence and association among
Canadians. Sleep 1994; 17: 739-43.
8. Hening W, Walters A, Allen R, Montplaisir J, Myers A,
Ferini-Strambi L. Impact, diagnosis and treatment of
restless legs syndrome (RLS) in a primary care population:
the REST (RLS epidemiology, symptoms, and treatment)
primary care study. Sleep Med 2004; 5: 237-46.
9. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters
AS and Montplaisi J. Restless legs syndrome: diagnostic
criteria, special considerations, and epidemiology. A
report from the restless legs syndrome diagnosis and
epidemiology workshop at the National Institutes of
Health. Sleep Med 2
10. Benediktsdottir B, Janson C, Lindberg E, Amardóttir
ES, Olafsson I, Cook E, et al. Prevalence of restless legs
syndrome among adults in Iceland and Sweden: Lung
function, comorbidity, ferritin, biomarkers and quality of
life. Sleep Med 2010; 11: 1043-8.
11. Benca R, Quintans J. Sleep and host defenses: a review.
Sleep 1997; 20:1027-37.
12. Irwin M, McClintick J, Costlow C, Fortner M, White J,
Gillin J. Partial night sleep deprivation reduces natural
killer and cellular immune responses in humans. FASEB J
1996; 10: 643-53.
13. Irwin M, Thompson J, Miller C, Gillin J, Ziegler M. Effects
of sleep and sleep deprivation on catecholamine and
interleukin-2 levels in humans: clinical implications. J Clin
Endocrinol Metab 1999; 84:1979-85.
14. Savard J, Laroche L, Simard S, Ivers H, Morin C. Chronic
insomnia and immune functioning. Psychosom Med 2003;
65:211-21.
15. Bonnet M, Arand D. Heart rate variability in insomniacs
and matched normal sleepers. Psychosom Med 1998; 60:
610-5.
16. Schwartz SW, Comoni-Huntley J, Cole SR, Hays JC, Blazer
DG, Schocken DD. Are sleep complaints an independent
risk factor for myocardial infarction? Ann Epidemiol 1998;
8:384-92.
17. Ayas NT, White DP, Manson JA, Stampfer MJ, Speizer FE,
Malhotra A, et al. A prospective study of sleep duration
and coronary heart disease in women. Arch Intem Med
2003; 163:205-9.
18. Meier-Ewert H, Ridker P, Rifai N, Regan M, Price N,
Dinges D, et al. Effect of sleep loss on C-reactive protein,
an inflammatory marker of cardiovascular risk. JACC
2004; 43: 678-83.
19. Rööst M, Nilsson P. Sleep disorders-metabolic implications
and long-term risks. Lákartidningen 2002; 99: 154-7.
20. Spiegel K, Ledproult R, van Cauter E. Impact of sleep
debt on metabolism and endocrine function. Lancet 1999;
354:1435-9.
21. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N,
Julius S. Relationship of tachycardia with high blood
pressure and metabolic abnormalities: a study with
mixture analysisin three populations. Hypertension 1997;
30:1267-73.
22. Björntorp P, Holm G, Rosmond R. Hypothalamic arousal,
insulin resistance and type 2 diabetes mellitus. Diab Med
1999; 16:373-83.
23. Michaud M, Chabli A, Lavigne G, Montplaisir J. Arm
restlessness in patients with restless legs syndrome. Mov
Disord 2000; 15: 289-93.
24. Allen RP, Earley CJ. Defining the phenotype of the restless
legs syndrome (RLS) using age-of-symptom-onset. Sleep
Med 2000; 1:11-9.
25. Winkelmann J, Muller-Myhsok B, Wittchen HU, Hock B,
Prager M, Pfister H, et al. Complex segregation analysis of
restless legs syndrome provides evidence for an autosomal
dominant mode of inheritance in early age at onset
families. Ann Neurol 2002; 52: 297-302.
26. Desai AV, Cherkas LF, Spector TD, Williams AJ. Genetic
influences in self-reported symptoms of obstructive sleep
apnoea and restless legs: a twin study. Twin Res 2004; 7:
589-95.
27. Ondo WG, Dat Vuong K, Wang Q. Restless legs syndrome
in monozygotic twins: clinical correlates. Neurology 2000;
55:1404-6.
28. Ekbom K, Ulfberg J. Restless legs syndrome (Review). J
IntemMed 2009; 266:419-31.
29. Nordlander NB. Therapy in restless legs. Acta Med Scand
1953; 145:453-7.
30. Kryger MH, Otake K, Foerster J. Low body stores of
iron and restless legs syndrome: a correctable cause of
insomnia in adolescents and teenagers. Sleep Med 2002; 3:
127-32.
31. Earley CJ, Heckler D, Allen RP. The treatment of restless
legs syndrome with intravenous iron dextran. Sleep Med
2004; 5:231-5.
32. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK,
Allen RP. Abnormalities in CSF concentrations of ferritin
and transferrin in restless legs syndrome. Neurology 2000;
54:1698-1700.
33. Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J.
CSF iron, ferritin, and transferrin levels in restless legs
syndrome. J Sleep Res 2005; 14:43-7.
34. Allen R. Dopamine and iron in the pathophysiology of
restless legs syndrome (RLS). Sleep Med 2004; 5:385-91.
35. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRl
measurement of brain iron in patients with restless legs
syndrome. Neurology 2001; 56: 263-5.
36. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP,
Ondo WG, et al. Neuropathological examination suggests
impaired brain iron acquisition in restless legs syndrome.
Neurology 2003; 61: 304-9.
37. Earley CJ, Barker PB, Horska A, Allen RP. MRI-determined
regional brain iron concentration in early- and late-onset
restless legs syndrome. Sleep Med 2006; 7:459-61.
38. Scales WE, Vander AJ, Brown MB, Kugler MJ. Human
circadian rhythms in temperature, trace metals, and blood
variables. J Appl Physiol 1988; 65:1840-6.
39. Rijsman RM, de Weerd AW, Stam CJ, Kerkhof GA, Rosman
JB. Periodic limb movement disorder and restless legs
syndrome in dialysis patients. Nephrology 2004; 9:353-61.
40. Collado-Seidel V, Kohnen R, Samtleben W, Hillebrand
GF, Oertel WH, Trenkwalder C. Clinical and biochemical
findings in uremic patients with and without restless legs
syndrome. Am J Kidney Dis 1998; 31: 324-8.
41. Winkelmann J, Stautner A, Samtleben W, Trenkwalder C.
Long-term course of restless legs syndrome in dialysis
patients after kidney transplantation. Mov Disord 2002; 17:
1072-6.
42. Rijsman RM, de Weerd AW. Secondary periodic limb
movement disorder and restless legs syndrome. Sleep
Med Rev 1999; 3:147-58.
43. Manconi M, Govoni V, De Vito A, Economou NT, Cesnik
E, Casetta I, et al. Restless legs syndrome and pregnancy.
Neurology 2004; 63:1065-9.
44. Polydefkis M, Allen RP, Hauer P, Earley CJ, Griffin JW,
McArthur JC. Subclinical sensory neuropathy in late-onset
restless legs syndrome. Neurology 2000; 55:1115-21.
45. Walters AS, Wagner M, Hening WA. Periodic Iimb
movements as the initial manifestation of restless legs
syndrome triggered by lumbosacral radiculopathy. Sleep
1996; 19: 825-6.
46. Walters AS, Hening W, Rubinstein M, Chokroverty
S. A clinical and polysomnographic comparison of
neuroleptic-induced akathisia and the idiopathic restless
legs syndrome. Sleep 1991; 14: 339-45.
47. Trenkwalder C, Paulus W, Walters AS. The restless legs
syndrome. Lancet Neurol 2005; 4:465-75.
48. Cervenka S, Palhagen SE, Comley RA Panagiotidis G,
Cselényi Z, Matthews JC, et al. Support for dopaminergic
hypoactivity in restless legs syndrome: a PET study on
D2-receptor binding. Brain 2006; 129: 2017-28.
49. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla
B. Restless legs syndrome improved by pramipexole. A
double-blind randomized trial. Neurology 1999; 52: 938-
43.
50. Montplaisir J, Denesle R, Petit D. Pramipexole in the
treatment of restless legs syndrome: a follow-up study. Eur
J Neurol 2000; 7 (suppl 1): 27-31.
51. Trenkwalder C, Garcia-Borreguero D, Montagna P,
Lainey E, de Weerd AW, Tidswell P, et al. Ropinirole in
the treatment of restless legs syndrome: results from the
TREAT RLS 1 study, a 12 week, randomised, placebo
controlled study in 10 European countries. J Neurol
Neurosurg Psychiatry 2004; 75:92-7.
52. Akpinar, S. Treatment of restless legs syndrome with
levodopa plus benserazide. Arch Neurol 1982; 39: 739.
53. Trenkwalder C, Collado Seidel V, Kazenwadel J, Wetter
TC, Oertel W, Selzer R, et al. One-year treatment with
standard and sustained-release levodopa: appropriate
long-term treatment of restless legs syndrome? Mov
Disord 2003; 18:1184-9.
54. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R,
Chokroverty S, et al. Successful treatment of the idiopathic
restless legs syndrome in a randomized double-blind trial
of oxycodone versus placebo. Sleep 1993; 16: 327-32.
55. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K,
Masramon X, Hemandez G. Treatment of restless legs
syndrome with gabapentin: a double-blind, cross-over
study. Neurology 2002; 59:1573-9.
56. Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P,
Nyberg-Hansen R. Treatment of the restless legs syndrome
with carbamazepine: a double blind study. Br Med J (Clin
Res Ed) 1984; 288:444-6.
57. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S.
Treatment of idiopathic restless legs syndrome (RLS) with
slow-release valproic acid compared with slow-release
levodopa/benserazid. J Neurol 2004; 251: 579-83.
58. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer
J. Gabapentin versus ropinirole in the treatment of
idiopathic restless legs syndrome. Neuropsychobiology
2003; 48: 82-6.
59. Thorp ML, Morris CD, Bagby SP. A crossover study of
gabapentin in treatment of restless legs syndrome among
hemodialysis patients. Am J Kidney Dis 2001; 38:104-8.
60. Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W,
Semler B, Zoghlami A, et al. Restless legs syndrome
(RLS) and periodic limb movement disorder (PLMD):
acute placebo-controlled sleep laboratory studies with
clonazepam. Eur Neuropsychopharmacol 2001; 11:153-61.
LÆKNAblaðið 2012/98 37